CN1526400A - 来源于管花肉苁蓉的含有苯乙醇苷的制剂及其制备方法和用途 - Google Patents
来源于管花肉苁蓉的含有苯乙醇苷的制剂及其制备方法和用途 Download PDFInfo
- Publication number
- CN1526400A CN1526400A CNA031192041A CN03119204A CN1526400A CN 1526400 A CN1526400 A CN 1526400A CN A031192041 A CNA031192041 A CN A031192041A CN 03119204 A CN03119204 A CN 03119204A CN 1526400 A CN1526400 A CN 1526400A
- Authority
- CN
- China
- Prior art keywords
- preparation
- phenethyl alcohol
- alcohol glycoside
- polar solvent
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229930182470 glycoside Natural products 0.000 title claims abstract description 85
- -1 phenethyl alcohol glycoside Chemical class 0.000 title claims abstract description 82
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-Phenylethanol Natural products OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims description 8
- 241000005787 Cistanche Species 0.000 title abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract description 109
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229930185474 acteoside Natural products 0.000 claims abstract description 27
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 claims abstract description 27
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 claims abstract description 24
- FSBUXLDOLNLABB-ISAKITKMSA-N echinacoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FSBUXLDOLNLABB-ISAKITKMSA-N 0.000 claims abstract description 21
- NJYVDFDTLLZVMG-UHFFFAOYSA-N echinacoside Natural products CC1OC(OC2C(O)C(OCCc3ccc(O)c(O)c3)OC(COC4OC(CO)C(O)C(O)C4O)C2OC(=O)C=Cc5cc(O)cc(O)c5)C(O)C(O)C1O NJYVDFDTLLZVMG-UHFFFAOYSA-N 0.000 claims abstract description 21
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 14
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 99
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 63
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- 241000336316 Cistanche tubulosa Species 0.000 claims description 32
- 239000000284 extract Substances 0.000 claims description 23
- 239000002798 polar solvent Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 15
- 239000003146 anticoagulant agent Substances 0.000 claims description 12
- 229940127219 anticoagulant drug Drugs 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000003480 eluent Substances 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 9
- 239000012046 mixed solvent Substances 0.000 claims description 9
- ILRCGYURZSFMEG-RKQHYHRCSA-N Salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RKQHYHRCSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- FNMHEHXNBNCPCI-QEOJJFGVSA-N Isoacteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O[C@H](COC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@H]1O FNMHEHXNBNCPCI-QEOJJFGVSA-N 0.000 claims description 7
- 150000002338 glycosides Chemical class 0.000 claims description 7
- FNMHEHXNBNCPCI-RYEKTNFUSA-N isoacteoside Natural products C[C@@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](COC(=O)C=Cc3ccc(O)c(O)c3)O[C@@H](OCCc4ccc(O)c(O)c4)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O FNMHEHXNBNCPCI-RYEKTNFUSA-N 0.000 claims description 7
- FPOYEEKZOOLVJA-WLLRULDYSA-N [(2s,4ar,6r,7r,8s,8ar)-2-(3,4-dihydroxyphenyl)-6-(hydroxymethyl)-8-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-3,4a,6,7,8,8a-hexahydro-2h-pyrano[2,3-b][1,4]dioxin-7-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@H]2O[C@@H](C=3C=C(O)C(O)=CC=3)CO[C@@H]2O[C@H](CO)[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 FPOYEEKZOOLVJA-WLLRULDYSA-N 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- ALERZNQPBWWLMW-UHFFFAOYSA-N 2''-acetylacteoside Natural products OC1C(O)C(O)C(C)OC1OC1C(OC(C)=O)C(OCCC=2C=C(O)C(O)=CC=2)OC(CO)C1OC(=O)C=CC1=CC=C(O)C(O)=C1 ALERZNQPBWWLMW-UHFFFAOYSA-N 0.000 claims description 4
- APXLKFCQWDJADY-VSALRCHLSA-N 2'-acetylacteoside Natural products C[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](OC(=O)C)[C@H](O)[C@H]1O APXLKFCQWDJADY-VSALRCHLSA-N 0.000 claims description 4
- FPOYEEKZOOLVJA-UHFFFAOYSA-N Crenatoside Natural products OC1C(O)C(O)C(C)OC1OC1C2OC(C=3C=C(O)C(O)=CC=3)COC2OC(CO)C1OC(=O)C=CC1=CC=C(O)C(O)=C1 FPOYEEKZOOLVJA-UHFFFAOYSA-N 0.000 claims description 4
- DORPKYRPJIIARM-UHFFFAOYSA-N Decaffeoylacteoside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(OCCC=2C=C(O)C(O)=CC=2)OC(CO)C1O DORPKYRPJIIARM-UHFFFAOYSA-N 0.000 claims description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 4
- DORPKYRPJIIARM-GYAWPQPFSA-N Verbasoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O[C@H](CO)[C@H]1O DORPKYRPJIIARM-GYAWPQPFSA-N 0.000 claims description 4
- KJJKGAYHJMZKLA-DBDAIDROSA-N [(2r,3r,4s,5r,6r)-5-acetyloxy-6-[2-(3,4-dihydroxyphenyl)ethoxy]-2-(hydroxymethyl)-4-[[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]methoxy]oxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1CO[C@@H]1[C@@H](OC(C)=O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O[C@H](CO)[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 KJJKGAYHJMZKLA-DBDAIDROSA-N 0.000 claims description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- XDAXWJHQKZRSEY-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-2-hydroxyethyl 4-O-[(E)-caffeoyl]-3-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1C(OC(=O)C=CC=2C=C(O)C(O)=CC=2)C(CO)OC(OCC(O)C=2C=C(O)C(O)=CC=2)C1O XDAXWJHQKZRSEY-UHFFFAOYSA-N 0.000 claims description 3
- YWJRHENUFPWISM-UHFFFAOYSA-N 3'-alpha-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1C(OC(=O)C=CC=2C=C(O)C(O)=CC=2)C(CO)OC(OCCC=2C=CC(O)=CC=2)C1O YWJRHENUFPWISM-UHFFFAOYSA-N 0.000 claims description 3
- SKWZAUHMKBQODM-LNMURLNHSA-N Campneoside I Natural products O=C(O[C@H]1[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](O)O2)[C@@H](O)[C@H](OC[C@H](OC)c2cc(O)c(O)cc2)C[C@@H]1CO)/C=C/c1cc(O)c(O)cc1 SKWZAUHMKBQODM-LNMURLNHSA-N 0.000 claims description 3
- KZLDMAIXPXOZCX-UHFFFAOYSA-N Tubuloside A Natural products OC1C(O)C(O)C(C)OC1OC1C(OC(C)=O)C(OCCC=2C=C(O)C(O)=CC=2)OC(COC2C(C(O)C(O)C(CO)O2)O)C1OC(=O)C=CC1=CC=C(O)C(O)=C1 KZLDMAIXPXOZCX-UHFFFAOYSA-N 0.000 claims description 3
- OBZROZJRGRPYKZ-IUKXOIARSA-N [(2r,3r,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)-2-methoxyethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]methoxy]oxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1OC[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O)OCC(OC)C=1C=C(O)C(O)=CC=1)C(=O)\C=C\C1=CC=C(O)C(O)=C1 OBZROZJRGRPYKZ-IUKXOIARSA-N 0.000 claims description 3
- JXRBUKCEZLRNOI-BRJAJVCCSA-N [(2r,3r,4s,5r,6r)-5-acetyloxy-6-[2-(3,4-dihydroxyphenyl)ethoxy]-2-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4-[[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]methoxy]oxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1CO[C@@H]1[C@@H](OC(C)=O)[C@H](OCCC=2C=C(O)C(O)=CC=2)O[C@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 JXRBUKCEZLRNOI-BRJAJVCCSA-N 0.000 claims description 3
- XDAXWJHQKZRSEY-XHJPSFMXSA-N beta-Hydroxyacteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCC(O)C=2C=C(O)C(O)=CC=2)[C@@H]1O XDAXWJHQKZRSEY-XHJPSFMXSA-N 0.000 claims description 3
- OWIYIDLFNMCIFO-UHFFFAOYSA-N campneosides I Natural products C=1C=C(O)C(O)=CC=1C(OC)COC(C(C1OC2C(C(O)C(O)C(C)O2)O)O)OC(CO)C1OC(=O)C=CC1=CC=C(O)C(O)=C1 OWIYIDLFNMCIFO-UHFFFAOYSA-N 0.000 claims description 3
- KMBRVOQNVGKLEX-UHFFFAOYSA-N cistantubuloside A Natural products OC1C(O)C(O)C(C)OC1OC1C(OC(=O)C=CC=2C=C(O)C(O)=CC=2)C(COC2C(C(O)C(O)C(CO)O2)O)OC(OCCC=2C=CC(O)=CC=2)C1O KMBRVOQNVGKLEX-UHFFFAOYSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 claims description 2
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000010828 elution Methods 0.000 description 30
- 239000012567 medical material Substances 0.000 description 21
- 238000012360 testing method Methods 0.000 description 21
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 239000000706 filtrate Substances 0.000 description 13
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000000274 adsorptive effect Effects 0.000 description 9
- 229960004526 piracetam Drugs 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000001035 drying Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 5
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 5
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 5
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 5
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 235000008504 concentrate Nutrition 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 5
- 229960002646 scopolamine Drugs 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229930184996 cistantubuloside Natural products 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229930189456 Campneoside Natural products 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- OWIYIDLFNMCIFO-HGTLEYCVSA-N [(2r,3r,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)-2-methoxyethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (e)-3-(3,4-dihydroxyphenyl)prop-2-enoate Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O)OCC(OC)C=1C=C(O)C(O)=CC=1)C(=O)\C=C\C1=CC=C(O)C(O)=C1 OWIYIDLFNMCIFO-HGTLEYCVSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000003446 memory effect Effects 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000308150 Orobanchaceae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- 229930194834 Syringalide Natural products 0.000 description 1
- 229930186414 Tubuloside Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- SHZGCJCMOBCMKK-HGVZOGFYSA-N alpha-L-rhamnopyranose Chemical compound C[C@@H]1O[C@@H](O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-HGVZOGFYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940067131 aspirin 100 mg Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 剂量mg/kg | 动物数(只) | 训练后到达目标 | 给酒精后到达目标 | ||||
时间(秒) | 错误次数/只数 | 时间(秒) | 错误次数/只数 | 错误率次/只 | 整组错误率次/只 | |||
苁蓉制剂脑复康对照 | 50200400400 | 1211101012 | 7.46±0.137.14±0.187.91±0.198.00±0.467.73±0.75 | 0/00/00/00/00/0 | 34.40±21.71*16.99±9.06##24.38±27.8424.08±32.5237.78±15.90 | 47/88/3ΔΔ46/754/662/10 | 5.882.676.579.006.20 | 3.920.734.605.405.17 |
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03119204 CN1268341C (zh) | 2003-03-04 | 2003-03-04 | 来源于管花肉苁蓉的含有苯乙醇苷的制剂及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03119204 CN1268341C (zh) | 2003-03-04 | 2003-03-04 | 来源于管花肉苁蓉的含有苯乙醇苷的制剂及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1526400A true CN1526400A (zh) | 2004-09-08 |
CN1268341C CN1268341C (zh) | 2006-08-09 |
Family
ID=34285014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03119204 Expired - Lifetime CN1268341C (zh) | 2003-03-04 | 2003-03-04 | 来源于管花肉苁蓉的含有苯乙醇苷的制剂及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1268341C (zh) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100387235C (zh) * | 2005-01-28 | 2008-05-14 | 北京华医神农医药科技有限公司 | 松果菊苷的制药新用途 |
WO2008116391A1 (fr) * | 2007-03-26 | 2008-10-02 | Sinphar Tian-Li Pharmaceutical Co., Ltd. (Hangzhou) | Promoteur de la prolifération de neuroblaste et promoteur de l'excroissance de neurite |
CN101129482B (zh) * | 2007-09-12 | 2010-12-08 | 新疆维吾尔自治区中药民族药研究所 | 从管花肉苁蓉中提取的组合物及其用途和提取方法 |
CN101353360B (zh) * | 2007-07-25 | 2010-12-29 | 北京华医神农医药科技有限公司 | 肉苁蓉总寡糖及其制备方法和用途 |
CN101143165B (zh) * | 2007-09-14 | 2011-07-27 | 中国药科大学 | 含管花肉苁蓉及其提取物治疗骨质疏松的组合物 |
CN102499322A (zh) * | 2009-09-30 | 2012-06-20 | 杏辉天力(杭州)药业有限公司 | 具有促进记忆改善的保健类食品或药品 |
CN102755341A (zh) * | 2012-07-12 | 2012-10-31 | 闫明 | 类叶升麻苷在制备防治阿尔茨海默病药物中的用途 |
CN103156867A (zh) * | 2011-12-16 | 2013-06-19 | 杏辉天力(杭州)药业有限公司 | 预防或治疗淀粉样β肽相关疾病或状况的医药组合物 |
JP2013528627A (ja) * | 2010-06-16 | 2013-07-11 | 杏輝天力(杭州)藥業有限公司 | イソアクテオシドまたはその製薬上許容される塩の使用 |
CN103251681A (zh) * | 2013-05-09 | 2013-08-21 | 暨南大学 | 一种沙苁蓉提取物及其制备方法和应用 |
CN103622980A (zh) * | 2013-12-12 | 2014-03-12 | 宁夏医科大学 | 肉苁蓉苯乙醇苷类化合物作为制备治疗骨质疏松症药物的应用及药物组合物 |
CN103816169A (zh) * | 2014-03-03 | 2014-05-28 | 新疆维吾尔自治区维吾尔医药研究所 | 类叶升麻苷在制备防治血管性痴呆药物中的应用 |
CN103896997A (zh) * | 2014-04-14 | 2014-07-02 | 青海伊纳维康生物科技有限公司 | 一种肉苁蓉中毛蕊花糖苷的分离纯化方法 |
CN104189099A (zh) * | 2014-06-17 | 2014-12-10 | 新疆医科大学 | 肉苁蓉苯乙醇苷提取物在防治高原病中的应用 |
CN104606297A (zh) * | 2015-02-11 | 2015-05-13 | 白心亮 | 一种管花肉苁蓉中活性成分的提取方法 |
WO2016000663A1 (zh) * | 2014-07-03 | 2016-01-07 | 杏辉天力(杭州)药业有限公司 | 管花肉苁蓉萃取物在制备保护眼部细胞的药物或食品中的用途 |
CN106389450A (zh) * | 2016-09-05 | 2017-02-15 | 江苏康缘药业股份有限公司 | campneoside II的用途 |
CN106420775A (zh) * | 2016-09-05 | 2017-02-22 | 江苏康缘药业股份有限公司 | crenatoside的用途 |
CN107513019A (zh) * | 2016-06-16 | 2017-12-26 | 江苏康缘药业股份有限公司 | 从中药红景天中提取的化合物、其制备方法及应用 |
CN109549943A (zh) * | 2019-02-12 | 2019-04-02 | 大连大学 | 一种促进牙周病骨修复的药物组合物 |
CN112608404A (zh) * | 2020-12-01 | 2021-04-06 | 石河子大学 | 一种氨基功能化异质结构多孔微球及其制备方法和应用 |
CN114478661A (zh) * | 2020-10-27 | 2022-05-13 | 杏辉天力(杭州)药业有限公司 | 一种由肉苁蓉萃取物中富集及分离苯乙醇苷类化合物的方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9339522B2 (en) * | 2013-05-30 | 2016-05-17 | Sinphar Pharmaceutical Co., Ltd. | Method for regulating blood glucose level |
CN106072642B (zh) * | 2016-06-28 | 2019-08-30 | 上海诺德生物实业有限公司 | 管花肉苁蓉水溶酚性提取物及其制备方法 |
-
2003
- 2003-03-04 CN CN 03119204 patent/CN1268341C/zh not_active Expired - Lifetime
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100387235C (zh) * | 2005-01-28 | 2008-05-14 | 北京华医神农医药科技有限公司 | 松果菊苷的制药新用途 |
WO2008116391A1 (fr) * | 2007-03-26 | 2008-10-02 | Sinphar Tian-Li Pharmaceutical Co., Ltd. (Hangzhou) | Promoteur de la prolifération de neuroblaste et promoteur de l'excroissance de neurite |
TWI465237B (zh) * | 2007-03-26 | 2014-12-21 | Sinphar Pharmaceutical Co Ltd | 神經芽細胞增殖促進劑及神經突起伸展劑 |
CN101657201B (zh) * | 2007-03-26 | 2014-04-09 | 杏辉天力(杭州)药业有限公司 | 神经芽细胞增殖促进剂及神经突起伸展剂 |
CN101353360B (zh) * | 2007-07-25 | 2010-12-29 | 北京华医神农医药科技有限公司 | 肉苁蓉总寡糖及其制备方法和用途 |
CN101129482B (zh) * | 2007-09-12 | 2010-12-08 | 新疆维吾尔自治区中药民族药研究所 | 从管花肉苁蓉中提取的组合物及其用途和提取方法 |
CN101143165B (zh) * | 2007-09-14 | 2011-07-27 | 中国药科大学 | 含管花肉苁蓉及其提取物治疗骨质疏松的组合物 |
CN102499322B (zh) * | 2009-09-30 | 2014-03-26 | 杏辉天力(杭州)药业有限公司 | 具有促进记忆改善的保健类食品或药品 |
CN102499322A (zh) * | 2009-09-30 | 2012-06-20 | 杏辉天力(杭州)药业有限公司 | 具有促进记忆改善的保健类食品或药品 |
JP2013528627A (ja) * | 2010-06-16 | 2013-07-11 | 杏輝天力(杭州)藥業有限公司 | イソアクテオシドまたはその製薬上許容される塩の使用 |
KR20150002576A (ko) * | 2011-12-16 | 2015-01-07 | 신파 티엔리 파머슈티컬 컴퍼니 리미티드 (항저우) | 아밀로이드 b 펩타이드 관련 질환 또는 이상을 예방 또는 치료하기 위한 약학적 조성물 |
CN103156867B (zh) * | 2011-12-16 | 2019-04-30 | 杏辉天力(杭州)药业有限公司 | 预防或治疗淀粉样β肽相关疾病或状况的医药组合物 |
KR102048289B1 (ko) * | 2011-12-16 | 2020-01-08 | 신파 티엔리 파머슈티컬 컴퍼니 리미티드 (항저우) | 아밀로이드 β 펩타이드 관련 질환 또는 이상을 예방 또는 치료하기 위한 약학적 조성물 |
WO2013087042A1 (zh) * | 2011-12-16 | 2013-06-20 | 杏辉天力(杭州)药业有限公司 | 预防或治疗淀粉样β肽相关疾病或状况的医药组合物 |
US20150087606A1 (en) * | 2011-12-16 | 2015-03-26 | Sinphar Tian-Li Pharmaceutical Co., Ltd. (Hangzhou) | Pharmaceutical composition for preventing or treating amyloid beta peptide-associated diseases or conditions |
CN103156867A (zh) * | 2011-12-16 | 2013-06-19 | 杏辉天力(杭州)药业有限公司 | 预防或治疗淀粉样β肽相关疾病或状况的医药组合物 |
CN102755341A (zh) * | 2012-07-12 | 2012-10-31 | 闫明 | 类叶升麻苷在制备防治阿尔茨海默病药物中的用途 |
CN103251681A (zh) * | 2013-05-09 | 2013-08-21 | 暨南大学 | 一种沙苁蓉提取物及其制备方法和应用 |
CN103622980A (zh) * | 2013-12-12 | 2014-03-12 | 宁夏医科大学 | 肉苁蓉苯乙醇苷类化合物作为制备治疗骨质疏松症药物的应用及药物组合物 |
CN103816169B (zh) * | 2014-03-03 | 2016-01-06 | 新疆维吾尔自治区维吾尔医药研究所 | 类叶升麻苷在制备防治血管性痴呆药物中的应用 |
CN103816169A (zh) * | 2014-03-03 | 2014-05-28 | 新疆维吾尔自治区维吾尔医药研究所 | 类叶升麻苷在制备防治血管性痴呆药物中的应用 |
CN103896997A (zh) * | 2014-04-14 | 2014-07-02 | 青海伊纳维康生物科技有限公司 | 一种肉苁蓉中毛蕊花糖苷的分离纯化方法 |
CN103896997B (zh) * | 2014-04-14 | 2016-07-06 | 青海伊纳维康生物科技有限公司 | 一种肉苁蓉中毛蕊花糖苷的分离纯化方法 |
CN104189099A (zh) * | 2014-06-17 | 2014-12-10 | 新疆医科大学 | 肉苁蓉苯乙醇苷提取物在防治高原病中的应用 |
WO2016000663A1 (zh) * | 2014-07-03 | 2016-01-07 | 杏辉天力(杭州)药业有限公司 | 管花肉苁蓉萃取物在制备保护眼部细胞的药物或食品中的用途 |
US10967029B2 (en) | 2014-07-03 | 2021-04-06 | Sinphar Pharmaceutical Co., Ltd. | Method of using Cistanche tubulosa extract to prevent, slow down, or treat an eye disease caused by oxidative stress |
RU2688939C2 (ru) * | 2014-07-03 | 2019-05-23 | СИНЬФАР ТЯНЬ-ЛИ ФАРМАСЬЮТИКАЛ Ко., ЭлТэДэ. (ХАНЧЖОУ) | Применение экстракта cistanche tubulosa в получении лекарственных средств или продуктов питания для защиты клеток глаза |
CN104606297A (zh) * | 2015-02-11 | 2015-05-13 | 白心亮 | 一种管花肉苁蓉中活性成分的提取方法 |
CN104606297B (zh) * | 2015-02-11 | 2017-04-26 | 内蒙古昶辉生物科技股份有限公司 | 一种管花肉苁蓉中活性成分的提取方法 |
CN107513019A (zh) * | 2016-06-16 | 2017-12-26 | 江苏康缘药业股份有限公司 | 从中药红景天中提取的化合物、其制备方法及应用 |
CN107513019B (zh) * | 2016-06-16 | 2020-06-26 | 江苏康缘药业股份有限公司 | 从中药红景天中提取的化合物、其制备方法及应用 |
CN106389450A (zh) * | 2016-09-05 | 2017-02-15 | 江苏康缘药业股份有限公司 | campneoside II的用途 |
CN106420775A (zh) * | 2016-09-05 | 2017-02-22 | 江苏康缘药业股份有限公司 | crenatoside的用途 |
CN109549943A (zh) * | 2019-02-12 | 2019-04-02 | 大连大学 | 一种促进牙周病骨修复的药物组合物 |
CN114478661A (zh) * | 2020-10-27 | 2022-05-13 | 杏辉天力(杭州)药业有限公司 | 一种由肉苁蓉萃取物中富集及分离苯乙醇苷类化合物的方法 |
CN112608404A (zh) * | 2020-12-01 | 2021-04-06 | 石河子大学 | 一种氨基功能化异质结构多孔微球及其制备方法和应用 |
CN112608404B (zh) * | 2020-12-01 | 2023-01-10 | 石河子大学 | 一种氨基功能化异质结构多孔微球及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1268341C (zh) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1268341C (zh) | 来源于管花肉苁蓉的含有苯乙醇苷的制剂及其制备方法和用途 | |
AU2004200624B2 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from herbaceous plant, cistanche tubulosa (schenk.) wight, process of making the same, and uses of the same | |
CN1699397A (zh) | 三七三醇皂苷的制备方法及其应用 | |
CN1931270A (zh) | 中药醒酒护肝药剂及其制备方法 | |
Ko et al. | Change of ginsenoside composition in ginseng extract by vinegar process | |
CN1528209A (zh) | 一种具有免疫调节、抗辐射功能的保健食品及其制备方法 | |
CN106008485A (zh) | 格列美脲的药物组合物及其在生物医药中的应用 | |
CN1236319A (zh) | 用于治疗丙型肝炎的含有黄柏皮和败酱的混合萃取物的药物组合物 | |
CN108524668B (zh) | 一种对药物性肝损伤具有修复和治疗作用的枸杞提取物的制备方法 | |
CN1186051C (zh) | 一种化痰止咳的药物及其生产方法 | |
CN101045077A (zh) | 一种胡芦巴口服固体制剂的制备方法及其应用 | |
CN1268323C (zh) | 一种圣地红景天软胶囊制剂及其制备方法 | |
CN1679648A (zh) | 脉络宁注射制剂及其制备方法和它的质量控制方法 | |
CN1194743C (zh) | 一种治疗类风湿性关节炎的中药组合物及其制备方法和质量控制方法 | |
CN114569625A (zh) | 绞股蓝皂苷用于制备戒毒药物中的应用 | |
CN1857588A (zh) | 一种仙灵骨葆制剂的质量控制方法 | |
CN1823982A (zh) | 舒肝健脾的中药制剂及其制备方法 | |
CN1186351C (zh) | 黄花倒水莲总皂苷及其药物组合物与制备方法 | |
CN1730023A (zh) | 一种抗肝炎病毒的中药制剂及其制备方法 | |
CN1176677C (zh) | 一种治疗冠心病的中药组合物及其制剂和制备方法 | |
CN1504232A (zh) | 抗流感病毒的药物有效部位及活性成分的分离制备方法 | |
EP1498131B1 (en) | Medicinal preparation containing phenylethanoid glycosides extracted from Cistanche tubulosa | |
CN1853701A (zh) | 一种洋参生脉药物的有效部位及其制备方法 | |
CN112717031B (zh) | 一种用于治疗阿尔茨海默症的药物组合物及其制备方法 | |
CN1785348A (zh) | 治疗ⅱ型糖尿病、降低血糖的中药复方制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: KANGYUAN PHARMCEUTICAL CO., LTD. Free format text: FORMER OWNER: XINGHUI TIANLI (HANGZHOU) PHARMACEUTICAL CO., LTD. Effective date: 20130515 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 311100 HANGZHOU, ZHEJIANG PROVINCE TO: 222047 LIANYUNGANG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130515 Address after: 222047 Jiangning economic and Technological Development Zone, Jiangsu, Lianyungang industrial city Patentee after: JIANGSU KANION PHARMACEUTICAL Co.,Ltd. Address before: 311100 No. 599 Hongfeng Road, Yuhang Economic Development Zone, Zhejiang, Hangzhou, China Patentee before: SINPHAR TIAN LI PHARMACEUTICAL Co.,Ltd. (HANGZHOU) |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20040908 Assignee: SINPHAR TIAN LI PHARMACEUTICAL Co.,Ltd. (HANGZHOU) Assignor: JIANGSU KANION PHARMACEUTICAL Co.,Ltd. Contract record no.: 2013330000204 Denomination of invention: Tubiflorous desert cistanche prepn containing phenethyl alcohol glycoside and its prepn process and use Granted publication date: 20060809 License type: Exclusive License Record date: 20130619 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CX01 | Expiry of patent term |
Granted publication date: 20060809 |
|
CX01 | Expiry of patent term |